Pacira | PCRX - Cost Of Sales


Pacira reported $50.74M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Assertio Holdings USD 8.89M 2.29M Jun/2024
Astellas Pharma JPY 129.43B 19.7B Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Cara Therapeutics USD 0 0 Mar/2025
Coherus Biosciences USD 4.04M 324K Dec/2025
Heron Therapeutics USD 11.12M 795K Dec/2025
Ironwood Pharmaceuticals USD 29.83M 560K Sep/2024
J&J USD 8.07B 103M Mar/2026
Ligand Pharmaceuticals USD 11.37M 8.38M Mar/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Novo Nordisk DKK 13.6B 1.55B Mar/2026
Omeros USD 33.16M 18.52M Jun/2024
Pacira USD 50.74M 3.89M Mar/2026
Perrigo USD 643.7M 103.7M Mar/2026
Pfizer USD 4.59B 1.7B Mar/2026
Supernus Pharmaceuticals USD 49.04M 1.5M Mar/2026
Teva Pharmaceutical Industries USD 2.01B 46M Mar/2026
Xeris Pharmaceuticals USD 13.66M 49K Dec/2025
Xoma 116K 112.7K Jun/2024
Zoetis USD 672M 71M Mar/2026